spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Recipharm and Laccure agree commercial collaboration

Recipharm Pharmaceutical Development AB

Leading contract development and manufacturing organisation (CDMO) Recipharm is entering into a collaboration with Laccure AB for the commercial manufacture and delivery of Laccure® Pessary

The new product, which has been developed to help women suffering from bacterial vaginosis, will be manufactured, packaged and distributed globally from Recipharm’s facility in Karlskoga that specialises in the production of semi-solid products.

Over the past years, Laccure AB has successfully taken the product from innovation through clinical studies to commercial manufacturing. The development work was focused on creating a highly effective antibiotic-free product that was also user-friendly in terms of being easy to apply and not messy to use. Recipharm and Laccure AB have now signed an agreement for commercial production of Laccure® Pessary and the exact date for the launch will be announced next year.

Laccure AB is a project company within the life science development organisation Partners for Development Investments in Life Sciences (P.U.L.S.). As it prepares for launch, the owner is endeavouring to sell the company to a buyer with the substantial resources required to bring the product to market.

Jeanette Robertsson, CEO of Laccure AB, said: “We are delighted to be collaborating with Recipharm, they are an expert partner that we can rely on for the commercial supply of our new product.

“Given the potential market for the product, a major benefit of partnering with Recipharm is that they have a high level of production capacity, which of course gives us the possibility to further scale up the batch size to meet market requirements in the future.”

It is estimated that more than 300 million women throughout the world suffer from bacterial vaginosis every year, however, there are currently no effective and safe products available that are also user-friendly and can be used with low-frequency dosages.

Laccure® Pessary is based on a patented substance that releases lactic acid, and only needs to be administered once to treat a bacterial vaginosis infection and then once a month to prevent a recurrence.

Ingela Palmkvist, General Manager at Recipharm in Karlskoga, said: “We are really looking forward to the commercial launch of this product, and contributing to something that will make a major difference to the lives of many women across the globe.”
web www.recipharm.com
 
Print this page
Send to a friend
   
spacer
News and Press Releases

CPhI India Report identifies two-tier manufacturing market and predicts increased acquisitions


More info >>


White Papers

Microalgae Culture Using the DASGIP® PBR4 Module for Illumination with a New Brunswick™ CelliGen® 310 Stirred-tank Bioreactor

Eppendorf

The number of bioprocess applications for microalgae has increased in recent years, particularly in the fi eld of biofuel production. The combination of the New Brunswick CelliGen 310 stirred-tank bioreactor and the DASGIP LED Illumination System creates a bioreactor setup which is capable of supporting high density microalgal growth. Using the stand-alone Eppendorf DASGIP PBR4 Module, LED illumination spectra and intensities can be controlled for optimal support of all types of chlorophylls and carotenoids. For this study in which high density culture of up to 1.5 x 107 cells/mL was achieved, the unicellular freshwater alga, Dunaliella tertiolecta, was used.
More info >>

Industry Events

Outsourcing in Clinical Trials New England

6-7 September 2017, Boston

Registration is now open for the flagship conference, OCT New England which will return to Boston this September. Following the tremendous success of the 2016 event, the OCT team have been busy putting together the most content driven, high quality agenda to date. The speaker line-up is the best so far, with senior professionals from across the field currently finalizing their interactive presentations and sessions.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement